Abstract
In this study, EGFR as a target for the anticancer activity of a series of 113 inhibitors were taken from the literature. Current work aims to derive statistically robust and appropriately validated multiple QSAR models using easily interpretable molecular descriptors and molecular docking analysis. It will be simpler to identify important structural trends and how they relate to anticancer activity as a result. The MLR model has been used to suggest some novel compounds with improved activity. It has been demonstrated how the predicted compounds interact with the enzyme using the docking study. All predicted compounds were discovered to have several hydrogen bonds with the receptor and involve their bulky groups in strong steric interactions with specific places of the enzyme. The proposed compounds exhibit good pharmacokinetic properties, according to the analysis of their pharmacokinetic profiles.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: British Journal of Multidisciplinary and Advanced Studies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
